Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Progesterone · 1 trial · 1 indication
Describe the concentration of progesterone (P4) in blood prior to, during and after 24 hours of DARE-PTB1 IVR (8mg and 12mg) over 14 days of use.
| Arm | Type | Description |
|---|---|---|
| DARE-PTB1 8mg IVR | EXPERIMENTAL | Intravaginal ring containing 8mg progesterone administered once for 14 days. |
| DARE-PTB1 12mg IVR | EXPERIMENTAL | Intravaginal ring containing 12mg progesterone administered once for 14 days. |
| DARE-PTB1 12mg IVR every 3 days | EXPERIMENTAL | Intravaginal ring containing 12mg progesterone administered every 3 days for 15 days. |
| Endometrin 100mg | ACTIVE_COMPARATOR | 100mg progesterone vaginal insert, three times daily for 14 days. |
| Name | Type | Description |
|---|---|---|
| Progesterone | DRUG | Each arm will administer different amounts of progesterone vaginally (8mg to 100mg) over a 14-15 day time period. |
Inclusion Criteria: * Individuals assigned female at birth who are post-menopausal, women 40 to 65 years of age, inclusive. Postmenopausal is defined as 6-months of spontaneous amenorrhea with serum FSH levels \> 40 mIU/mL (if not taking systemic hormone therapy) or 6 weeks postsurgical bilateral o...
Progesterone is being developed by Dare Bioscience, Inc. for the prevention of Pre Term Birth. It is a small molecule drug that acts as an agonist of the PGR (progesterone receptor) target. The drug is currently in Phase 1 clinical development and is being studied in a clinical trial to compare its pharmacokinetics.
Progesterone targets the PGR (progesterone receptor) and acts as an agonist. This means it binds to and activates the progesterone receptor, which is involved in maintaining pregnancy. The drug is being studied for its potential to prevent Pre Term Birth.
Progesterone is being developed by Dare Bioscience, Inc., a biopharmaceutical company. The company is conducting clinical trials to evaluate the drug for the prevention of Pre Term Birth. Dare Bioscience, Inc. is listed on the stock exchange under the ticker symbol DARE.
Progesterone is currently in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is designed to study the drug's pharmacokinetics in healthy volunteers.
Progesterone is being studied in a Phase 1 clinical trial with the identifier NCT06668896. The trial is titled 'Comparing the Pharmacokinetics of a Progesterone Ring Versus a Progesterone Vaginal Insert' and is expected to enroll 60 female participants aged 40 years and older. The trial is not yet recruiting.
Progesterone is a naturally occurring hormone and is the active ingredient in various pharmaceutical products. The drug being developed by Dare Bioscience, Inc. is a specific formulation of progesterone, and the ongoing clinical trial is comparing a progesterone ring to a progesterone vaginal insert.